MANAGEMENT OF OSTEOARTHRITIS OF THE HIP: SURGICAL OPTIONS AND OUTCOMES
International Journal of Drug Delivery Technology · 05.06.2026 · 16 (49s)
DOI: 10.25258/ijddt.16.49s.151 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 05.06.2026. Verfasst von Nishchaiy Nasa und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Osteoarthritis (OA) of the hip is a chronic progressive degenerative disorder characterized by gradual deterioration of articular cartilage, remodeling of subchondral bone, osteophyte formation, pain, stiffness, and increasing functional disability. It is among the leading causes of chronic musculoskeletal impairment worldwide, particularly in the elderly population, and has a substantial impact on mobility, independence, daily functioning, and overall quality of life. The development of hip osteoarthritis is multifactorial and involves a combination of biomechanical stress, inflammatory mediators, genetic predisposition, metabolic influences, and age-related degenerative changes that ultimately result in progressive joint destruction. In the early stages, conservative treatment modalities such as physiotherapy, weight management, analgesics, nonsteroidal antiinflammatory drugs, activity modification, lifestyle changes, and intra-articular injections may help reduce symptoms and improve functional capacity. Nevertheless, many patients with advanced disease continue to experience persistent pain and severe limitation of activities, eventually necessitating surgical management. The choice of surgical treatment depends on several factors including patient age, severity of joint degeneration, activity level, functional requirements, and the underlying pathology affecting the hip joint. Joint-preserving procedures, including osteotomy and hip arthroscopy, may provide symptomatic improvement and delay disease progression in selected younger individuals with early osteoarthritis and structural deformities. Hip resurfacing arthroplasty has emerged as a bone-conserving option for carefully selected active patients, while arthrodesis and hemiarthroplasty currently play a more limited role in modern orthopedic practice. Total hip replacement (THR) continues to be regarded as the definitive surgical treatment for end-stage hip osteoarthritis because of its reliable outcomes in relieving pain, restoring mobility, correcting deformity, and improving quality of life. Continuous advancements in implant design, bearing surfaces, fixation methods, minimally invasive surgical techniques, robotic-assisted procedures, and perioperative rehabilitation strategies have further enhanced implant longevity, functional recovery, and patient satisfaction. This narrative review discusses the pathophysiology of hip osteoarthritis, indications for surgical intervention, and the spectrum of surgical treatment modalities including osteotomy, hip arthroscopy, hip resurfacing, arthrodesis, hemiarthroplasty, and total hip replacement. In addition, the review examines postoperative functional outcomes, complications, revision arthroplasty, rehabilitation protocols, and recent innovations in hip arthroplasty techniques. Emphasis is placed on appropriate patient selection, individualized implant choice, perioperative optimization, and multidisciplinary rehabilitation approaches to achieve favorable long-term clinical outcomes.
Zitieren
APA
Nasa, N., Kala, S., Deswal, A., & Dhakla, S. (2026). MANAGEMENT OF OSTEOARTHRITIS OF THE HIP: SURGICAL OPTIONS AND OUTCOMES. International Journal of Drug Delivery Technology, 16(49s). https://doi.org/10.25258/ijddt.16.49s.151
Vancouver
Nasa N, Kala S, Deswal A, Dhakla S. MANAGEMENT OF OSTEOARTHRITIS OF THE HIP: SURGICAL OPTIONS AND OUTCOMES. International Journal of Drug Delivery Technology. 2026;16(49s). doi:10.25258/ijddt.16.49s.151
BibTeX
@article{Nasa2026,
author = {Nasa, Nishchaiy and Kala, Shivang and Deswal, Aman and Dhakla, Shivam},
title = {MANAGEMENT OF OSTEOARTHRITIS OF THE HIP: SURGICAL OPTIONS AND OUTCOMES},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {49s},
doi = {10.25258/ijddt.16.49s.151}
}
EUVIMED